Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo

Japanese Journal of Cancer Research

Volumn 89, Issue 12, 1998, Pages 1343-1351

  Fujimoto, Shuichi ^a   Chikazawa, Hirotaka ^b  

^a CHIBA CANCER CENTER   (Japan)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Combination chemotherapy; In vivo; M 109 murine lung carcinoma; Paclitaxel; Schedule dependency

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PACLITAXEL; RANIMUSTINE; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032456506     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00532.x     Document Type: Article

References (26)

1. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K. and Donehower, R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med.,111, 273-279 (1989).
2. Holmes, F. A., Walters, R. S., Theriault, R. T., Forman, A. D., Newton, L. K., Raber, M. N., Buzdar, A. U., Frye, D. K. and Hortobagyi, G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst.,83, 1797-1805 (1991).
3. Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., Krakoff, I. H. and Hong, W. K. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst.,85, 384-388 (1993).
4. Rao, S., Horwitz, S. B. and Ringel, I. Direct photoaffinity labeling of tubulin with taxol. J. Natl. Cancer Inst.,84, 785-787 (1992).
5. Schiff, P. B., Fant, J. and Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-667 (1979).
6. Madoc-Jones, H. and Mauro, F. Interphase action of vinblastine and vincristine: differences in their lethal actions through the mitotic cycle of cultured mammalian cells. J. Cell Physiol.,72, 185-196 (1968).
7. Schiff, P. B. and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77, 1561-1565 (1980).
8. Milross, C. G., Peters, L. J., Hunter, N. R., Mason, K. A. and Milas, L. Sequence-dependent antitumor activity of paclitaxel (Taxol) and cisplatin in vivo. Int. J. Cancer, 62, 599-604 (1995).
9. Knick, V. C., Eberwein, D. J. and Miller, C. G. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J. Natl. Cancer Inst., 87, 1072-1077 (1995).
10. Rose, W. C. Taxol: a review of its preclinical in vivo anti-tumor activity. Anticancer Drugs, 3, 311-321 (1992).
11. Fujimoto, S. Schedule dependency of IV-paclitaxel against SC-M109 mouse lung cancer. Jpn. J. Cancer Chemother.,21, 671-677 (1994) (in Japanese).
12. Corbett, T. H., Griswold, D. P., Jr., Roberts, B. J., Peckham, J. C. and Schabel, F. M., Jr. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinoma. Cancer, 40, 2660-2680 (1977).
13. Geran, R. I., Greenberg, N. R., Macdonald, M. M., Schumacher, A. M. and Abott, B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., Part 3, 3, 1-103 (1972).
14. Speicher, L. A., Barone, L. and Tew, K. D. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res.,52, 4433-4440 (1992).
15. Chou, T. C., Motzer, R. J., Tong, Y. and Bosl, G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst.,86, 1517-1524 (1994).
16. Jordan, M. A., Toso, R. J., Thrower, D. and Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA, 90, 9552-9556 (1993).
17. Kumar, N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem.,256, 10435-10441 (1981).
18. Christen, R. D., Jekunen, A. P., Jones, J. A., Thiebaut, F., Shalinsky, D. R. and Howell, S. B. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J. Clin. Invest.,92, 431-440 (1993).
19. Liebmann, J. E., Fisher, J., Teague, D. and Cook, J. A. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol. Res.,6, 25-31 (1994).
20. Kubota, T., Matsuzaki, S. W., Hoshiya, Y., Watanabe, M., Kitajima, M., Asanuma, F., Yamada, Y. and Koh, J. Anti-tumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J. Surg. Oncol.,64, 115-121 (1997).
21. Donaldson, K. L., Goolsby, G. L. and Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57, 847-855 (1994).
22. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B. and Donehower, R. C. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol.,9, 1692-1703 (1991).
23. Skipper, H. E., Schabel, F. M., Jr., Mellett, B., Montgomery, J. A., Wilkoff, L. J., Lloyd, H. H. and Brockman, W. R. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep.,54, 431-450 (1970).
24. Lawrence, T. S. Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells. Cancer Res.,48, 725-730 (1988).
25. Yang, L., Rowe, T. C. and Liu, L. F. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res.,45, 5872-5876 (1985).
26. Hahn, S. M., Liebmann, J. E., Cook, J., Fisher, J., Goldspiel, B., Venzon, D., Mitchell, J. B. and Kaufmann, D. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer, 72, 2705-2711 (1993).